Lantern Pharma Valuation
| LTRN Stock | USD 3.07 0.06 1.92% |
At this time, the firm appears to be undervalued. Lantern Pharma secures a last-minute Real Value of $7.39 per share. The latest price of the firm is $3.07. Our model forecasts the value of Lantern Pharma from analyzing the firm fundamentals such as Shares Owned By Insiders of 14.74 %, current valuation of 5.45 M, and Return On Equity of -0.45 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lantern Pharma's valuation include:
Price Book 1.2488 | Enterprise Value 5.5 M | Enterprise Value Ebitda 0.2137 |
Undervalued
Today
Please note that Lantern Pharma's price fluctuation is slightly risky at this time. Calculation of the real value of Lantern Pharma is based on 3 months time horizon. Increasing Lantern Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lantern Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lantern Stock. However, Lantern Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.07 | Real 7.39 | Target 20.5 | Hype 3.02 |
The intrinsic value of Lantern Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lantern Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lantern Pharma helps investors to forecast how Lantern stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lantern Pharma more accurately as focusing exclusively on Lantern Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lantern Pharma's intrinsic value based on its ongoing forecasts of Lantern Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lantern Pharma's closest peers.
Lantern Pharma Cash |
|
Lantern Valuation Trend
Knowing Lantern Pharma's actual value is paramount for traders when making sound investment determinations. Using both Lantern Pharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Lantern Pharma Total Value Analysis
Lantern Pharma is now projected to have valuation of 5.45 M with market capitalization of 33.76 M, debt of 234.47 K, and cash on hands of 62.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lantern Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.45 M | 33.76 M | 234.47 K | 62.15 M |
Lantern Pharma Asset Utilization
One of the ways to look at asset utilization of Lantern is to check how much profit was generated for every dollar of assets it reports. Lantern Pharma secures a negative usage of assets of -0.28 %, losing $0.002807 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Lantern Pharma shows how discouraging it operates for each dollar spent on its assets.Lantern Pharma Ownership Allocation
The market capitalization of Lantern Pharma is $33.76 Million. Lantern Pharma secures 14.74 % of its outstanding shares held by insiders and 24.1 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Lantern Pharma Profitability Analysis
Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0.About Lantern Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lantern Pharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lantern Pharma based exclusively on its fundamental and basic technical indicators. By analyzing Lantern Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lantern Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lantern Pharma. We calculate exposure to Lantern Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lantern Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -174.8 K | -166.1 K |
Lantern Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 10.8 M |
Lantern Pharma Current Valuation Indicators
Lantern Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lantern Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lantern Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lantern Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lantern Pharma's worth.When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.